Profitability
Weight: 20%
F
0
- 5yr Avg ROIC -131.7%
- Operating Margin Trend -60.99 pp/yr
CHRS
Coherus Oncology, Inc.
AlphaQuality composite grade, weighted for stable earnings power businesses.
⚠ 4 of the last 5 fiscal years showed negative net income — AlphaQuality will not grade above F for persistent unprofitability in a stable earnings power business.
Grade overrides the 6.2 pillar composite — hard gates always win.
Capital Efficiency
Weight: 15%
F
0
- 5yr Avg ROE -314.2%
- 5yr Share-Count CAGR 12.4%
Growth Quality
Weight: 15%
F
15
- 5yr Revenue CAGR -40.1%
- 5yr EPS CAGR 0.0%
- Revenue-Growth Years (5) 2/5
Cash Generation
Weight: 15%
F
0
- 5yr FCF Margin -106.3%
- 5yr FCF/NI Conversion -0.72x
Balance Sheet
Weight: 20%
F
0
- Net Debt / EBITDA 10.00x
- Interest Coverage (EBIT/Int) -19.95x
- Altman Z-Score -8.44
Stability
Weight: 15%
F
27
- EPS Volatility (σ/μ) 0.68
- Piotroski F-Score 3
- Negative-Revenue Years (5) 3/5
Guru Flow
Curated superinvestor sentiment — not part of the AlphaQuality grade.Not enough curated-guru data to call a flow.
- Wood new